Moreover, two distinct CLK inhibitors were reported to increase the skipping of exon 7 in the RPS6KB1 gene, a splicing event directly correlated with the anti‐proliferative effects of these drugs in breast cancer models [94, 96]. Here, CLK1 is linked to breast cancer.